| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
JQKD-82 targets KDM5 (histone demethylase). KDM5 is a histone demethylase that removes methyl groups from histone H3 lysine 4 (H3K4me3), leading to transcriptional repression. JQKD82 binds the catalytic domain of KDM5 and inhibits its demethylase activity. This increases H3K4me3 levels but paradoxically inhibits downstream MYC-driven transcriptional output. It is a useful tool compound to block KDM5A.
|
|---|---|
| ln Vitro |
The global H3K4me3 level of MM.1S cells increases in response to JQKD82 (0.3 μM; 24 hours)[1]. In a dose- and time-dependent way, JQKD82 (0.1-10 μM; day 1-day 5) suppresses the development of MM.1S cells. In MM.1S cells, JQKD82 has a strong growth inhibition effect (IC50=0.42 μM)[1]. In MM.1S and MOLP-8 cells, JQKD82 (1 μM; 24 hours) causes G1 cell-cycle arrest by 48 hours[1].
In vitro, JQKD82 is a cell-permeable and selective KDM5 inhibitor (MM.1S cells, IC50 = 0.42 uM). It increases histone H3K4me3 but paradoxically inhibits downstream MYC-driven transcriptional output in vitro and in vivo. It is a useful tool compound to block KDM5A. |
| ln Vivo |
The anti-multiple myeloma activity of JQKD82 (50-75 mg/kg; ip; twice a day for 3 weeks) has been reported[1]. JQKD82 exhibits a significant decrease in MYC immuno-staining in vivo and a rise in H3K4me3 levels[1].
In vivo, JQKD82 has demonstrated antitumor activity in animal models of multiple myeloma. It inhibits MYC-driven transcriptional output in vivo. It is a research compound for multiple myeloma. |
| Enzyme Assay |
For non-cell enzyme assays, recombinant KDM5 is incubated with JQKD82 and a methylated peptide substrate (e.g., H3K4me3) in assay buffer containing cofactors. Demethylation is measured by Western blot, ELISA, or mass spectrometry. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
In cell assays, multiple myeloma cell lines (e.g., MM.1S) are treated with serial dilutions of JQKD82. Cell viability is measured by MTT or CellTiter-Glo. H3K4me3 levels are measured by Western blot. MYC-driven transcriptional output is measured by qPCR.
|
| Animal Protocol |
Animal/Disease Models: Sixweeks old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (bearing MOLP-8 TurboGFP-Luc cells)[1]
Doses: 50 mg/kg, 75 mg/kg Route of Administration: ip ; twice a day for 3 weeks Experimental Results: Dramatically decreased tumor burden. In vivo animal protocols use mice bearing multiple myeloma xenografts. JQKD82 is dissolved in DMSO/PEG/saline and administered intraperitoneally or orally. Tumor volume and survival are assessed. Pharmacokinetic parameters are determined by LC-MS. |
| References |
| Molecular Formula |
C27H40N4O5
|
|---|---|
| Molecular Weight |
500.63
|
| Exact Mass |
500.3
|
| Elemental Analysis |
C, 53.16; H, 7.11; Cl, 17.43; N, 9.18; O, 13.11
|
| CAS # |
2410512-38-6
|
| Related CAS # |
JQKD82 trihydrochloride;2863676-87-1
|
| PubChem CID |
146374976
|
| Appearance |
Solid powder
|
| LogP |
3.1
|
| tPSA |
93.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
36
|
| Complexity |
660
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=CC(CNCC(N(CCN(C)C)CC)=O)=NC=C1)OC2=CC=C(C=C2OC(C)C)OC(C)C
|
| InChi Key |
APYABXFXNNTCQD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H40N4O5/c1-8-31(14-13-30(6)7)26(32)18-28-17-22-15-21(11-12-29-22)27(33)36-24-10-9-23(34-19(2)3)16-25(24)35-20(4)5/h9-12,15-16,19-20,28H,8,13-14,17-18H2,1-7H3
|
| Chemical Name |
[2,4-di(propan-2-yloxy)phenyl] 2-[[[2-[2-(dimethylamino)ethyl-ethylamino]-2-oxoethyl]amino]methyl]pyridine-4-carboxylate
|
| Synonyms |
JQKD82 HCl; JQKD82 hydrochloride; JQKD82; JQKD-82; JQKD 82; PCK82; PCK-82; PCK 82;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9975 mL | 9.9874 mL | 19.9748 mL | |
| 5 mM | 0.3995 mL | 1.9975 mL | 3.9950 mL | |
| 10 mM | 0.1997 mL | 0.9987 mL | 1.9975 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.